KROS Stock Risk & Deep Value Analysis
Keros Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KROS Stock
We analyzed Keros Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KROS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
KROS Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for KER-050 or KER-012
- 📅
Significant quarterly cash burn exceeding projections without key pipeline advancement
- 📅
Increased competitive pressure from rival therapies in development
Unlock KROS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Keros Therapeutics Inc (KROS) Do?
Market Cap
$334.90M
Sector
Healthcare
Industry
Biotechnology
Employees
148
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit Keros Therapeutics Inc WebsiteInvestment Thesis
Keros Therapeutics is a speculative high-risk, high-reward biotech opportunity with significant 10x growth potential driven by its deep pipeline of differentiated TGF-β modulators. While facing recent financial setbacks from earnings misses and substantial cash deployment for share buybacks, the long cash runway into H1 2028 and critical upcoming Phase 2/3 data readouts for KER-050 and KER-012 provide clear catalysts for a substantial re-rating, particularly given its small market cap and unmet medical needs in its target areas.
Is KROS Stock Undervalued?
Unlock the full AI analysis for KROS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
KROS Price Targets & Strategy
12-Month Target
$20.00
Bull Case
$35.00
Bear Case
$5.00
Valuation Basis
Based on discounted future pipeline value given early-stage biotech, reflecting an ~80% upside from current levels towards analyst consensus target of $21.86.
Entry Strategy
Consider dollar-cost averaging in the $10.00-$12.00 range, utilizing current price levels near recent support.
Exit Strategy
Take initial profit at $20.00, reassess for further upside post-catalysts. Set a stop loss at $8.00 to manage downside risk.
Portfolio Allocation
10% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is KROS Financially Healthy?
Valuation
P/E Ratio
6.04
Profitability
Gross Margin
37.19%
Operating Margin
18.84%
Net Margin
26.12%
Return on Equity
10.43%
EPS
$1.57
Balance Sheet
Total Debt
$17.43M
Cash & Equivalents
$693.47M
Cash Flow
EBITDA
$47.93M
Other
Beta (Volatility)
0.87
Does KROS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability relies on successful clinical trial outcomes, regulatory approvals, patent protection, and market adoption of its novel TGF-β modulators, with the Takeda partnership providing external validation.
Moat Erosion Risks
- •Clinical trial failures or delays for lead candidates
- •Erosion of intellectual property through generic competition or alternative therapies
- •Challenging regulatory landscape for novel treatments
KROS Competitive Moat Analysis
Sign up to see competitive advantages
KROS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Neutral to Slightly Negative (Average analyst rating 'Hold', HC Wainwright cut Q1 2026 EPS estimate)
Insider Activity (Form 4)
New director Charles W. Newton filed initial beneficial ownership (Form 3) on March 11, 2026. No Form 4 filings for buys/sells by individuals in the last 90 days.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Q4 2025 earnings were a significant miss on revenue and EPS, potentially leading to increased stock price volatility around future reports.
Key Metrics to Watch
Competitive Position
Top Competitor
Other biotech companies targeting hematological/musculoskeletal disorders or the TGF-β pathway (specific competitor not detailed in provided data).
Market Share Trend
Not applicable; company is pre-commercial with pipeline in development.
Valuation vs Peers
Valuation metrics are unavailable, but the company trades at a discount to analyst price targets, suggesting potential undervaluation based on pipeline.
Competitive Advantages
- •Differentiated mechanisms of action for TGF-β modulators
- •Broad pipeline addressing multiple large unmet medical needs
- •Strategic partnership with Takeda validating platform technology
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive KROS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (expected)
- •Phase 2/3 data readouts for KER-050 (for anemia) and KER-012 (for myelofibrosis/other indications)
Medium-Term (6-18 months)
- •Initiation of pivotal Phase 3 trials for lead candidates
- •Potential new strategic partnerships or expanded indications for existing pipeline assets
Long-Term (18+ months)
- •Regulatory approvals and commercialization of first-in-class TGF-beta modulators
- •Establishment as a market leader in specialized hematological and musculoskeletal disorder treatments
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KROS?
- ✓
Positive clinical trial data for KER-050 and KER-012
- ✓
Further strategic partnerships or licensing deals
- ✓
Improvements in quarterly cash burn and sustainable operational efficiency
Bull Case Analysis
See what could go right with Premium
Competing with KROS
See how Keros Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Keros Therapeutics Inc KROS | $334.9M | 7.8 | 6.0 | $244.1M | 26.1% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $154.6B | 0.2 | 19.9 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Keros Therapeutics Inc (KROS)?
As of March 22, 2026, Keros Therapeutics Inc has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Keros Therapeutics Inc?
Keros Therapeutics Inc's market capitalization is approximately $334.9M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Keros Therapeutics Inc use?
KROS is the ticker symbol for Keros Therapeutics Inc. The company trades on the NGM.
What is the risk level for KROS stock?
Our analysis rates Keros Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of KROS?
Keros Therapeutics Inc currently has a price-to-earnings (P/E) ratio of 6.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Keros Therapeutics Inc's revenue growing?
Keros Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is KROS stock profitable?
Keros Therapeutics Inc has a profit margin of 26.1%. This indicates strong profitability.
How often is the KROS DVR analysis updated?
Our AI-powered analysis of Keros Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 22, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KROS (Keros Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.